{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:32:01Z","timestamp":1791325921539,"version":"4.3.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T00:00:00Z","timestamp":1412553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0108694","type":"journal-article","created":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T17:48:28Z","timestamp":1412617708000},"page":"e108694","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":79,"title":["A Multicenter Phase I\/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00684918","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Aaron D.","family":"Schimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Goard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,10,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"E Estey","year":"2006","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"R Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: Leukemia. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html\" xlink:type=\"simple\">http:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html<\/ext-link>. Accessed: 2014 Apr 17."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"JE Chipuk","year":"2010","journal-title":"Mol Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"S Cory","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"SP Glaser","year":"2012","journal-title":"Genes Dev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1133289","article-title":"Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak","volume":"315","author":"SN Willis","year":"2007","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"M Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","article-title":"Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins","volume":"13","author":"D Zhai","year":"2006","journal-title":"Cell Death Differ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"M Konopleva","year":"2008","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","article-title":"Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma","volume":"16","author":"JJ Hwang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"SM O'Brien","year":"2009","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2011-11-391037","article-title":"Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"119","author":"Y Oki","year":"2012","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"AD Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLML.2010.n.059","article-title":"Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis","volume":"10","author":"SA Parikh","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Raza A, Galili N, Borthakur G, Carter TH, Claxton DF, et al. (2009) A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 27: suppl; abstr 3579.","DOI":"10.1200\/jco.2009.27.15_suppl.3579"},{"key":"ref17","unstructured":"National Cancer Instititute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf\" xlink:type=\"simple\">http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf<\/ext-link>. Accessed: 2014 Apr 17."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"BD Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1073\/pnas.0711647105","article-title":"Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons","volume":"105","author":"H Li","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1073\/pnas.95.10.5789","article-title":"Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity","volume":"95","author":"D Offen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2011.05.005","article-title":"A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer","volume":"74","author":"PK Paik","year":"2011","journal-title":"Lung Cancer"},{"key":"ref22","first-page":"9","article-title":"Bcl-2 family-regulated apoptosis in health and disease","volume":"2","author":"G Dewson","year":"2010","journal-title":"Cell Health Cytoskel"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2005-03-1283","article-title":"Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells","volume":"106","author":"M Thomas","year":"2005","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V92.2.383","article-title":"Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes","volume":"92","author":"DJ Izon","year":"1998","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/cddis.2012.109","article-title":"Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B","volume":"3","author":"RW Rooswinkel","year":"2012","journal-title":"Cell Death Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"C Tse","year":"2008","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"AW Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"WH Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","article-title":"BCL2\/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation","volume":"117","author":"M Vogler","year":"2011","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08669.x","article-title":"Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas","volume":"153","author":"EA Brem","year":"2011","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.exphem.2006.07.008","article-title":"Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells","volume":"34","author":"C Campas","year":"2006","journal-title":"Exp Hematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1182\/blood-2011-09-378141","article-title":"Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process","volume":"119","author":"M Rahmani","year":"2012","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0108694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T03:28:12Z","timestamp":1650338892000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0108694"}},"subtitle":[],"editor":[{"given":"Maria R.","family":"Baer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,6]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0108694","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,6]]}}}